Vera Therapeutics, Inc. Weighted Average Number of Shares Outstanding, Basic and Diluted
Vera Therapeutics, Inc. (VERA) reported Weighted Average Number of Shares Outstanding, Basic and Diluted of 24.23 million shares for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-16.
Discontinued › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted · last filed 2022-05-16
- Vera Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2022-03-31 was 24.23M shares, a 6186.25% increase year-over-year.
- Vera Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-12-31 was 21.36M shares, a 6759.73% increase year-over-year.
- Vera Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-09-30 was 21.27M shares, a 6423.47% increase year-over-year.
- Vera Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-06-30 was 10.50M shares, a 3133.54% increase year-over-year.
- Vera Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for fiscal 2021 was 13.44M shares, a 4099.14% increase from fiscal 2020.
- Vera Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for fiscal 2020 was 319.96K shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic and Diluted 3 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 6 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 9 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2022-03-31 | 24.23M shares 10-Q · filed 2022-05-16 | 22.79M shares derived: average of 2 quarters · filed 2022-05-16 | 22.29M shares derived: average of 3 quarters · filed 2022-05-16 | 19.34M shares derived: average of 4 quarters · filed 2022-05-16 |
| 2021-12-31 | 21.36M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | 21.31M shares derived: average of 2 quarters · filed 2022-03-28 | 17.71M shares derived: average of 3 quarters · filed 2022-03-28 | 13.44M shares 10-K · filed 2022-03-28 |
| 2021-09-30 | 21.27M shares 10-Q · filed 2021-11-10 | 15.88M shares derived: average of 2 quarters · filed 2021-11-10 | 10.79M shares 10-Q · filed 2021-11-10 | 8.12M shares derived: average of 4 quarters · filed 2022-05-16 |
| 2021-06-30 | 10.50M shares 10-Q · filed 2021-08-16 | 5.47M shares 10-Q · filed 2021-08-16 | 3.73M shares derived: average of 3 quarters · filed 2022-05-16 | 2.88M shares derived: average of 4 quarters · filed 2022-05-16 |
| 2021-03-31 | 385.40K shares 10-Q · filed 2022-05-16 | 348.41K shares derived: average of 2 quarters · filed 2022-05-16 | 340.94K shares derived: average of 3 quarters · filed 2022-05-16 | 336.88K shares derived: average of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | 311.42K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | 318.70K shares derived: average of 2 quarters · filed 2022-03-28 | 320.71K shares derived: average of 3 quarters · filed 2022-03-28 | 319.96K shares 10-K · filed 2022-03-28 |
| 2020-09-30 | 325.99K shares 10-Q · filed 2021-11-10 | 325.35K shares derived: average of 2 quarters · filed 2021-11-10 | 322.81K shares 10-Q · filed 2021-11-10 | |
| 2020-06-30 | 324.72K shares 10-Q · filed 2021-08-16 | 321.21K shares 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | 317.69K shares 10-Q · filed 2021-06-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |